A PHASE 1, SINGLE-ASCENDING DOSE, MULTIPLE-ASCENDING DOSE, AND MULTI DOSE SAFETY, TOLERABILITY, PHARAMCOKINETICS, AND PHARACODYNAMICS STUDY OF SUBCUTANEOUSLY ADMINISTERED ALN-AS1 IN PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP)

Project: Other project

StatusFinished
Effective start/end date1/22/161/21/19

Funding

  • Alnylam Pharmaceuticals, Inc: $226,712.68